StockData
ABVC BioPharma, Inc. logo

ABVC BioPharma, Inc. (ABVC) stock

ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.96−0.03 (-3.03%)

Close on Nov 12, 2026Market cap $25.59MP/E –Yield –

ABVC BioPharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

ABVC BioPharma's ebitda for the twelve months ending Sep 30, 2023 was -$9.36M. For fiscal 2022 it was -$15.09M. The highest annual figure on record is -$153.40K in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$15.09M–
FY2021Dec 31, 2021-$11.69M–
FY2013Sep 30, 2013-$153.40K–
FY2012Sep 30, 2012-$1.11M–
FY2011Sep 30, 2011-$1.85M–
FY2010Sep 30, 2010-$1.84M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2023CQ3 2023Sep 30, 2023-$2.15M–
Q2 FY2023CQ2 2023Jun 30, 2023-$2.19M–
Q1 FY2023CQ1 2023Mar 31, 2023-$1.90M–
Q4 FY2022CQ4 2022Dec 31, 2022-$3.13M–
Q3 FY2022CQ3 2022Sep 30, 2022-$3.71M–
Q2 FY2022CQ2 2022Jun 30, 2022-$2.04M–
Q1 FY2022CQ1 2022Mar 31, 2022-$6.21M–
Q4 FY2021CQ4 2021Dec 31, 2021-$6.44M–
Q3 FY2021CQ3 2021Sep 30, 2021-$1.97M–

More ABVC BioPharma figures

See a number that looks wrong?